Orphan designation: Selumetinib Treatment of amyotrophic lateral sclerosis, 13/12/2023 Positive
Orphan designation: Selumetinib Treatment of amyotrophic lateral sclerosis, 13/12/2023 Positive
Orphan designation: Selumetinib Treatment of amyotrophic lateral sclerosis, 13/12/2023 Positive
Human medicines European public assessment report (EPAR): Ambirix, hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed), Date of authorisation: 30/08/2002, Revision: 18, Status: Authorised
pseudoephedrine
Committee for Herbal Medicinal Products (HMPC): 20-22 November 2023, European Medicines Agency, Amsterdam, the Netherlands, 20 November 2023
Saxenda (liraglutide) supply shortage
Methodology European Specialised Expert Community
Human medicines European public assessment report (EPAR): Twinrix Adult, hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed), Date of authorisation: 19/09/1996, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Twinrix Paediatric, hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed), Date of authorisation: 10/02/1997, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Strensiq, asfotase alfa, Date of authorisation: 28/08/2015, Revision: 17, Status: Authorised
Cibinqo-H-C-005452-P46-005 : EPAR - Assessment Report - Variation